We use cookies to deliver our online services. Details of the cookies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you agree to our use of cookies. To close this message click close.

Reverse Mergers Between German and U.S. Biotech Companies

11 December 2006

Bio-Science Law Review
Many private German biotech companies are facing difficulties in raising capital and, as a result, are finding public listings in more established markets increasingly attractive.  Some German biotechs have applied a creative structure to overcome these difficulties, such as the 'reverse merger' into a publicly held U.S. company, as a way of accessing US capital markets. This article explores this transaction model, commonly found within the U.S. biotech sector, as an attractive model for German biotechs.
Loading data